Literature DB >> 32560359

Liposome-Embedding Silicon Microparticle for Oxaliplatin Delivery in Tumor Chemotherapy.

Armando Cevenini1,2, Christian Celia3,4, Stefania Orrù2,5,6, Daniela Sarnataro1, Maddalena Raia2, Valentina Mollo7, Marcello Locatelli3, Esther Imperlini6, Nicoletta Peluso1,2, Rosa Peltrini1,2,8, Enrica De Rosa4, Alessandro Parodi6,9, Luigi Del Vecchio1,2, Luisa Di Marzio3, Massimo Fresta10, Paolo Antonio Netti7,11, Haifa Shen4,12, Xuewu Liu4, Ennio Tasciotti2,13,14, Francesco Salvatore1,2.   

Abstract

Mesoporous silicon microparticles (MSMPs) can incorporate drug-carrying nanoparticles (NPs) into their pores. An NP-loaded MSMP is a multistage vector (MSV) that forms a Matryoshka-like structure that protects the therapeutic cargo from degradation and prevents its dilution in the circulation during delivery to tumor cells. We developed an MSV constituted by 1 µm discoidal MSMPs embedded with PEGylated liposomes containing oxaliplatin (oxa) which is a therapeutic agent for colorectal cancer (CRC). To obtain extra-small liposomes able to fit the 60 nm pores of MSMP, we tested several liposomal formulations, and identified two optimal compositions, with a prevalence of the rigid lipid 1,2-distearoyl-sn-glycero-3-phosphocholine and of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]. To improve the MSV assembly, we optimized the liposome-loading inside the MSMP and achieved a five-fold increase of the payload using an innovative lyophilization approach. This procedure also increased the load and limited dimensional changes of the liposomes released from the MSV in vitro. Lastly, we found that the cytotoxic efficacy of oxa-loaded liposomes and-oxa-liposome-MSV in CRC cell culture was similar to that of free oxa. This study increases knowledge about extra-small liposomes and their loading into porous materials and provides useful hints about alternative strategies for designing drug-encapsulating NPs.

Entities:  

Keywords:  colon cancer; liposome; mesoporous silicon microparticle; multistage vector; nanoparticle; oxaliplatin

Year:  2020        PMID: 32560359     DOI: 10.3390/pharmaceutics12060559

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  7 in total

Review 1.  Liposomes: structure, composition, types, and clinical applications.

Authors:  Hamdi Nsairat; Dima Khater; Usama Sayed; Fadwa Odeh; Abeer Al Bawab; Walhan Alshaer
Journal:  Heliyon       Date:  2022-05-13

Review 2.  Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases.

Authors:  Sureshbabu Ram Kumar Pandian; Kevin Kumar Vijayakumar; Sankaranarayanan Murugesan; Selvaraj Kunjiappan
Journal:  Heliyon       Date:  2022-06-04

3.  Pharmaceutical Development and Design of Thermosensitive Liposomes Based on the QbD Approach.

Authors:  Dorina Gabriella Dobó; Zsófia Németh; Bence Sipos; Martin Cseh; Edina Pallagi; Dániel Berkesi; Gábor Kozma; Zoltán Kónya; Ildikó Csóka
Journal:  Molecules       Date:  2022-02-24       Impact factor: 4.411

Review 4.  Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy.

Authors:  Buhle Buyana; Tobeka Naki; Sibusiso Alven; Blessing Atim Aderibigbe
Journal:  Int J Mol Sci       Date:  2022-09-24       Impact factor: 6.208

Review 5.  Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer.

Authors:  Kangkang Ying; Bingjun Bai; Xing Gao; Yuzi Xu; Hangxiang Wang; Binbin Xie
Journal:  Front Bioeng Biotechnol       Date:  2021-07-07

6.  Proteomics Reveals that Methylmalonyl-CoA Mutase Modulates Cell Architecture and Increases Susceptibility to Stress.

Authors:  Michele Costanzo; Marianna Caterino; Armando Cevenini; Vincent Jung; Cerina Chhuon; Joanna Lipecka; Roberta Fedele; Ida Chiara Guerrera; Margherita Ruoppolo
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

Review 7.  Secretome Proteomic Approaches for Biomarker Discovery: An Update on Colorectal Cancer.

Authors:  Armando Cevenini; Stefania Orrù; Esther Imperlini
Journal:  Medicina (Kaunas)       Date:  2020-08-31       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.